Highlights:
Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune system
People with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ lives
For more than…
Shots:
SLE-related diseases like CLE and IIM are characterized by strong type I interferon involvement. The proven efficacy of Saphnelo (anifrolumab) in SLE lays the foundation for its potential use in CLE and IIM
Recently, AstraZeneca initiated two new P-III trials, LAVENDER and JASMINE, to evaluate Saphnelo in cutaneous lupus erythematosus and idiopathic inflammatory myopathies …
Shots:
A UK observational study spanning 17 years shows a 2.9-fold increase in Cardiac Amyloidosis diagnoses, highlighting significant progress in awareness among healthcare professionals and advancements in diagnostic tools
The study underscores the importance of improving the identification and treatment of Cardiac Amyloidosis, particularly in cases with overlapping conditions such as heart failure
Mina Makar,…
Shots:
Biogen recently shared findings from the P-II/III DEVOTE study, which investigated the safety and efficacy of a higher dose regimen of Spinraza for the treatment of spinal muscular atrophy (SMA)
Stephanie Fradette, Head of Neuromuscular Development Unit at Biogen, joins PharmaShots for a stimulating conversation on Biogen's groundbreaking presentation at World Muscle Society 2024. …
Shots:
Misfolded TTR can lead to chronic conditions like ATTRv-PN or ATTR-CM. AstraZeneca’s Wainua (eplontersen) is a once-a-month RNA-targeted medication that suppresses TTR production
Mina Makar SVP and Commerical Lead of the Global Cardiovascular, Renal, and Metabolism (CVRM), Biopharmaceuticals Business Unit at AstraZeneca, sheds light on eplontersen and its ongoing P-III clinical trial on ATTR-CM …
Pharma has reached a crossroads, where the promise of science and innovation has met the reality of access issues, inefficiencies and shifting customer expectations.
So where do you go from here? Keep going down a path that’s clearly not working, or take a risk and innovate for the future?
You need to commit to a…
Join us for Reuters Events Digital Health 2025 on 12-13 May in Nashville, where we tackle the critical issues plaguing the healthcare sector today. As organizations face a stretched workforce and an outdated digital infrastructure, the urgency for transformation has never been greater. Current models of care are unsustainable, especially when addressing the diverse needs of an…
Where disruption meets direction
In the past year, pharma has witnessed disruption in the external environment and internal restructure. We’ve reorganized for patients and customers – but it’s one thing to change a job title, another to transform outcomes.
But how do you plan for the next wave of change across technology, regulations and expectations?
For over…
Get ready for the 3rd Cell & Gene Therapy Research & Development Congress Asia!
Imbued with the latest scientific developments, clinical stage studies, and success stories in the field, the two-day event kicks off on April 10th at Hotel Fort Canning, Singapore. The topics for sessions include emerging technology, regulatory landscapes and ethical considerations, stem…
Shots:
Johnson & Johnson’s (J&J) Tremfya recently received its third approval from the US FDA, supported by the pivotal QUASAR study, which demonstrated significant remission after one year of treatment in adults with moderately to severely active ulcerative colitis
Tremfya is a dual-binding monoclonal antibody targeting interleukin 23 (IL-23), a cytokine responsible for inflammation
At…

